FDA postpones panel meeting to review Sarepta's DMD drug

(Reuters) - The U.S. Food and Drug Administration postponed a meeting of its advisory panel to review Sarepta Therapeutics Inc's drug for a rare muscle wasting disorder due to inclement weather forecast for Washington DC.